{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:20:27Z","timestamp":1790835627838,"version":"4.1.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Over the last 25\u200ayears, the role of autologous hematopoietic stem cell transplant (HSCT) in the treatment of diffuse cutaneous systemic sclerosis (dcSSc) has been elucidated. However, multiple critical questions remain regarding this therapy. Of particular interest is the role of HSCT in the treatment of systemic sclerosis (SSc)-associated interstitial lung disease since this is the leading cause of death in SSc.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Most clinical trials and observational studies of HSCT for the treatment of dcSSc have reported pulmonary outcomes as secondary outcomes, Also, most studies have excluded patients with significant pulmonary function impairment. Despite these limitations, there is increasing evidence that suggests that HSCT leads to interstitial lung disease stabilization and possibly improvement of lung function based on pulmonary function tests and imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>HSCT has demonstrated improved long-term outcomes compared to conventional therapies for dcSSC. Future research is needed to refine or expand patient selection, optimize conditioning regimens, and evaluate the potential role of maintenance immunosuppression. We recommend an increased focus on interstitial lung disease since this is the primary cause of death in SSc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001050","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T14:02:16Z","timestamp":1727704936000},"page":"410-419","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Autologous hematopoietic stem cell transplant for systemic sclerosis associated interstitial lung disease"],"prefix":"10.1097","volume":"36","author":[{"given":"Jana","family":"Zielonka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Paul","family":"Higuero Sevilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1183\/16000617.00002915","article-title":"Interstitial lung disease in systemic sclerosis: where do we stand?","volume":"24","author":"Cappelli","year":"2015","journal-title":"Eur Respir Rev"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous nonmyeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs. intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan Keith","year":"2018","journal-title":"N Engl J Med"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1073\/pnas.82.8.2483","article-title":"Rationale for bone marrow transplantation in the treatment of autoimmune diseases","volume":"82","author":"Ikehara","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaut.2018.06.002","article-title":"Hematopoietic stem cell therapy for autoimmune diseases \u2212 clinical experience and mechanisms","volume":"92","author":"Alexander","year":"2018","journal-title":"J Autoimmun"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0140-6736(05)64864-7","article-title":"Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation","volume":"349","author":"Tyndall","year":"1997","journal-title":"Lancet"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.3390\/cells11233912","article-title":"Hematopoietic cell transplantation for systemic sclerosis \u2013 a review","volume":"11","author":"Levin","year":"2022","journal-title":"Cells"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1093\/rheumatology\/keac628","article-title":"Improving outcomes in scleroderma: recent progress of cell-based therapies","volume":"62","author":"Khanna","year":"2023","journal-title":"Rheumatology"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1002\/art.39748","article-title":"Review: hematopoietic stem cell transplantation for scleroderma: effective immunomodulatory therapy for patients with pulmonary involvement","volume":"68","author":"Sullivan","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"941011","DOI":"10.3389\/fimmu.2022.941011","article-title":"Reconstitution of the immune system and clinical correlates after stem cell transplantation for systemic sclerosis","volume":"13","author":"Kawashima-Vasconcelos","year":"2022","journal-title":"Front Immunol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1399-3062.2009.00401.x","article-title":"Infectious complications in patients receiving autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases","volume":"11","author":"Kohno","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3390\/cells11050843","article-title":"Autologous haematopoietic stem cell transplantation and systemic sclerosis: focus on interstitial lung disease","volume":"11","author":"Bagnato","year":"2022","journal-title":"Cells"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2147\/JBM.S338077","article-title":"Life after autologous hematopoietic stem cell transplantation for systemic sclerosis","volume":"12","author":"Moraes","year":"2021","journal-title":"J Blood Med"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14397595.2017.1416920","article-title":"Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: Long-term follow-up on a phase II trial and treatment-related fatal cardiomyopathy","volume":"28","author":"Nakamura","year":"2018","journal-title":"Mod Rheumatol"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/bloodadvances.2017010041","article-title":"Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases","volume":"1","author":"Snowden","year":"2017","journal-title":"Blood Adv"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41409-021-01355-1","article-title":"Long term outcomes of the French ASTIS systemic sclerosis cohort using the global rank composite score","volume":"56","author":"Ait Abdallah","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R19-20250526","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211035196","article-title":"Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all","volume":"13","author":"Spierings","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/acr.24785","article-title":"Clinical and molecular findings after autologous stem cell transplantation or cyclophosphamide for scleroderma: handling missing longitudinal data","volume":"75","author":"Keyes-Elstein","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood-2007-02-072389","article-title":"High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study","volume":"110","author":"Nash","year":"2007","journal-title":"Blood"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/bmt.2016.211","article-title":"Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis","volume":"52","author":"Del Papa","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/annrheumdis-2020-217058","article-title":"Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study","volume":"79","author":"van Bijnen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bjd.15993","article-title":"Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of the literature","volume":"178","author":"Eyraud","year":"2018","journal-title":"Br J Dermatol"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s42358-021-00166-8","article-title":"Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience","volume":"61","author":"Henrique-Neto","year":"2021","journal-title":"Adv Rheumatol"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2019.230128","article-title":"Autologous stem cell transplantation for progressive systemic sclerosis: a prospective noninterventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party","volume":"106","author":"Henes","year":"2021","journal-title":"Haematologica"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41409-020-0978-2","article-title":"Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5\u200adays","volume":"56","author":"Burt","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1378\/chest.13-2626","article-title":"Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review","volume":"146","author":"Winstone","year":"2014","journal-title":"Chest"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/acr.24451","article-title":"Evolution of systemic sclerosis-associated interstitial lung disease one year after hematopoietic stem cell transplantation or cyclophosphamide","volume":"74","author":"Ciaffi","year":"2022","journal-title":"Arthritis Care Res"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/rheumatology\/kew259","article-title":"Quantitative chest CT analysis in patients with systemic sclerosis before and after autologous stem cell transplantation: comparison of results with those of pulmonary function tests and clinical tests","volume":"55","author":"Kloth","year":"2016","journal-title":"Rheumatology"},{"issue":"(SI)","key":"R32-20250526","doi-asserted-by":"crossref","first-page":"SI32","DOI":"10.1093\/rheumatology\/keac319","article-title":"Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous haematopoietic stem cell transplantation","volume":"62","author":"Pugnet","year":"2023","journal-title":"Rheumatology"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/ard.60.6.577","article-title":"Phase I\/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease","volume":"60","author":"Binks","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bbmt.2018.06.025","article-title":"Systemic sclerosis as an indication for autologous hematopoietic cell transplantation: position statement from the American Society for Blood and Marrow Transplantation","volume":"24","author":"Sullivan","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"e044483","DOI":"10.1136\/bmjopen-2020-044483","article-title":"A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol","volume":"11","author":"Spierings","year":"2021","journal-title":"BMJ Open"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T17:18:46Z","timestamp":1748279926000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001050","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]}}}